Larimar Therapeutics, Inc. LRMR
Institutional shares held
64.6 Million
93.5K
calls
68K
puts
Total value of holdings
$214M
$309K
calls
$225K
puts
Market Cap
$143M
43,269,200
Shares Out.
Institutional ownership
149.32%
# of Institutions
113
We take great care to ensure that the data presented and summarized in this overview for Larimar Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LRMR
View all-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$70.3 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$20 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$18.4 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$15.8 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$11.3 Million6.65% of portfolio
-
Black Rock Inc. New York, NY3.13MShares$10.4 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.67MShares$8.84 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.22MShares$7.34 Million0.0% of portfolio
-
Opaleye Management Inc. Boston, MA1.91MShares$6.34 Million1.13% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.44MShares$4.77 Million0.01% of portfolio
Latest Institutional Activity in LRMR
Top Purchases
Top Sells
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Insider Transactions at LRMR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2025
|
Michael Celano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,185
+16.1%
|
-
|
|
Jan 22
2025
|
Carole Ben Maimon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
91,000
+19.03%
|
-
|
|
Jan 22
2025
|
Russell Clayton Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,306
+33.72%
|
-
|
|
Jan 22
2025
|
Gopi Shankar Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,306
+31.45%
|
-
|
|
Feb 16
2024
|
Thomas Edward Hamilton Director |
BUY
Open market or private purchase
|
Direct |
57,208
+9.2%
|
$457,664
$8.74 P/Share
|
|
Feb 16
2024
|
James E Flynn Director |
BUY
Open market or private purchase
|
Indirect |
4,290,617
+21.03%
|
$34,324,936
$8.74 P/Share
|
|
Feb 14
2024
|
Frank E Thomas Director |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$22,000
$11.0 P/Share
|
|
Jan 17
2024
|
Carole Ben Maimon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,125
+16.57%
|
-
|
|
Jan 17
2024
|
Russell Clayton Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+50.0%
|
-
|
|
Jan 17
2024
|
Michael Celano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+17.83%
|
-
|
|
Jan 17
2024
|
Gopi Shankar Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+45.0%
|
-
|
|
Dec 07
2023
|
Gopi Shankar Chief Development Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$15,000
$3.73 P/Share
|
|
May 17
2023
|
Joseph Truitt Director |
BUY
Open market or private purchase
|
Direct |
2,750
+50.0%
|
$8,250
$3.73 P/Share
|
|
May 17
2023
|
Carole Ben Maimon President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+1.84%
|
$15,000
$3.7 P/Share
|
|
May 17
2023
|
Michael Celano Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.25%
|
$15,000
$3.73 P/Share
|
|
Jan 31
2023
|
Carole Ben Maimon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
205,000
+43.91%
|
-
|
|
Jan 31
2023
|
Michael Celano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
76,000
+41.36%
|
-
|
|
Sep 16
2022
|
Thomas Edward Hamilton Director |
BUY
Open market or private purchase
|
Direct |
317,460
+38.48%
|
$952,380
$3.15 P/Share
|
|
Sep 16
2022
|
James E Flynn Director |
BUY
Open market or private purchase
|
Indirect |
11,111,108
+40.28%
|
$33,333,324
$3.15 P/Share
|
|
Sep 16
2022
|
Michael Celano Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
31,746
+50.0%
|
$95,238
$3.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
172K
Shares
From
4
Insiders
| Grant, award, or other acquisition | 172K shares |
|---|
Sell / Disposition
0
Shares
From
0
Insiders